What We Do
We develop novel, best-in-class multispecific biologics for the treatment of cancer. By harnessing cutting-edge technology and a deep understanding of oncology, we strive to revolutionize antibody research and development, and ultimately treatment outcomes.
The 92Bio Team
Meet the passionate and experienced minds driving innovation at 92Bio.
Ben Buelow CEO
Suhasini Iyer
CDO
Patrick Koenig
VP, Biologics
Investors and Partners
